{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T21:38:39Z","timestamp":1768599519450,"version":"3.49.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We describe a case of a 74-year-old woman with germline <jats:italic toggle=\"yes\">BRCA2<\/jats:italic> mutation, with an incidental diagnosis of metastatic thymoma presenting as a mediastinal mass with cardiac muscle and lymph node involvement. Despite surgical and radiotherapy treatment, there was marked advancement with new lung and liver metastases. All lesions demonstrated <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT uptake, and the patient received 4 peptide receptor radionuclide therapy cycles with <jats:sup>177<\/jats:sup>Lu-DOTATATE, with pronounced reduction in the size of the liver, cardiac, and pleural lesions. This is the first case to demonstrate partial response to peptide receptor radionuclide therapy in metastatic thymoma, thus suggesting possible treatment option to refractory and advancing metastatic thymoma.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004553","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:29:52Z","timestamp":1675348192000},"page":"e190-e192","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A Case of Metastatic Thymoma Responsive to Treatment With 177Lu-DOTATATE"],"prefix":"10.1097","volume":"48","author":[{"given":"Reut","family":"Halperin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Urban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Tirosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/ejcts\/ezv426","article-title":"State of the art: diagnostic tools and innovative therapies for treatment of advanced thymoma and thymic carcinoma","volume":"49","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/med-21-11","article-title":"Systemic treatments for thymic tumors: a narrative review","volume":"5","year":"2021","journal-title":"Mediastinum"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/jcem.85.4.6547","article-title":"Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro","volume":"85","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"823667","DOI":"10.3389\/fonc.2022.823667","article-title":"Correlation of somatostatin receptor 2 expression, 68Ga-DOTATATE PET scan and octreotide treatment in thymic epithelial tumors","volume":"12","year":"2022","journal-title":"Front Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/cancers14030774","article-title":"The never-ending history of octreotide in thymic tumors: a vintage or a contemporary drug?","volume":"14","year":"2022","journal-title":"Cancers (Basel)"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"810419","DOI":"10.3389\/fonc.2021.810419","article-title":"Imaging evaluation of thymoma and thymic carcinoma","volume":"11","year":"2022","journal-title":"Front Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"e0168215","DOI":"10.1371\/journal.pone.0168215","article-title":"Octreotide LAR and prednisone as neoadjuvant treatment in patients with primary or locally recurrent unresectable thymic tumors: a phase II study","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","article-title":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","volume":"146","year":"2021","journal-title":"Eur J Cancer"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/RLU.0000000000000733","article-title":"Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:05:38Z","timestamp":1750536338000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004553","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,14]]}}}